{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T04:04:27Z","timestamp":1750565067937,"version":"3.41.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The treatment of metastatic pheochromocytoma is challenging. We report a case of a woman with recurrent pheochromocytoma with multiple metastases who achieved excellent response after 4 cycles of <jats:sup>177<\/jats:sup>Lu-DOTATATE therapy. She did not experience any observable adverse effects. Her disease was still stable 6 months after the fourth cycle of treatment.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004994","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T06:00:20Z","timestamp":1701756020000},"page":"338-339","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["177Lu-DOTATATE in the Treatment of Recurrent Pheochromocytoma With Multiple Metastases"],"prefix":"10.1097","volume":"49","author":[{"given":"Dan","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/ejso.2002.1413","article-title":"The management of benign and malignant pheochromocytoma and abdominal paraganglioma","volume":"29","year":"2003","journal-title":"Eur J Surg Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00000658-199906000-00001","article-title":"Clinical experience over 48 years with pheochromocytoma","volume":"229","year":"1999","journal-title":"Ann Surg"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1141648","DOI":"10.3389\/fonc.2023.1141648","article-title":"Peptide receptor radionuclide therapy in advanced pheochromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"13","year":"2023","journal-title":"Front Oncol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 assessment","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.esmoop.2021.100171","article-title":"Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials","volume":"6","year":"2021","journal-title":"ESMO Open"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RLU.0000000000002915","article-title":"Peptide receptor radionuclide therapy using 225Ac-DOTATOC achieves partial remission in a patient with progressive neuroendocrine liver metastases after repeated \u03b2-emitter peptide receptor radionuclide therapy","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/RLU.0000000000003792","article-title":"225Ac-DOTATOC\u2013targeted somatostatin receptor \u03b1-therapy in a patient with metastatic neuroendocrine tumor of the thymus, refractory to \u03b2-radiation","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/RLU.0000000000004139","article-title":"177Lu-DOTATATE PRRT for multiple unusual metastatic sites in neuroendocrine tumor","volume":"47","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:05:54Z","timestamp":1750532754000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004994","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2023,12,2]]}}}